BBIO

BridgeBio Pharma
D

BBIO

82.650
USD
-0.29
(-0.35%)
قبل الجلسة·84.050USD+1.400(+1.69%)
حجم التداول
9,727
الربح لكل سهم
-2
العائد الربحي
-
P/E
-23
حجم السوق
16,135,991,972
أصول ذات صلة المقالات
المزيد

العنوان: BridgeBio Pharma

القطاع: الرعاية الصحية
الصناعة: Biotechnology
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.